drugset / Trial / NCT06114641

Effectiveness & Safety of Ovine Enoxaparin Sodium to Originator Enoxaparin in Non-ST-Segment Elevation ACS Patients

NCT06114641

Phase 4 Completed 220 enrolled PT Bio Farma
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The aim of this study is evaluating safety and effectiveness of Ovine Enoxaparin Sodium in Non-ST-Segment Elevation Acute Coronary Syndrome (NSTEACS) Patients

Timeline

Start
2023-06-01
Primary completion
2024-02-05
Completion
2024-08-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Enoxaparin sodium Other / unclassified 1 mg/kg Intravenous

Indications

No indication recorded.